[关键词]
[摘要]
目的 探讨蟾酥注射液抑制胃癌细胞增殖的作用及其潜在机制。方法 采用CCK-8实验、克隆形成实验、流式细胞术及Hoechst 33342染色考察蟾酥注射液对HGC-27细胞增殖、周期与凋亡的影响。通过网络药理学筛选蟾酥治疗胃癌的靶点,利用蛋白质组学技术分析蟾酥注射液处理HGC-27细胞后的差异表达蛋白,取二者交集确定关键靶点。通过基因富集分析预测核心信号通路,并采用Western blotting进行验证。通过体外沉默糖原合成酶激酶-3β(glycogen synthase kinase-3β,GSK-3β)和过表达细胞周期蛋白E1(cyclin E1,CCNE1)的功能回复实验,以及基于裸鼠移植瘤模型的体内实验,进一步验证核心分子轴的功能。结果 蟾酥注射液能显著抑制HGC-27细胞增殖,其半数抑制浓度(half inhibitory concentration,IC50)值为26.56 ng/mL。蟾酥注射液能诱导细胞周期阻滞于G0/G1期并促进细胞凋亡(P<0.01)。网络药理学与蛋白质组学共同筛选出29个关键靶点,富集分析提示磷脂酰肌醇3-激酶(phosphatidylinositol 3-kinase,PI3K)/蛋白激酶B(protein kinase B,Akt)信号通路是核心通路。Western blotting结果显示,蟾酥注射液可下调HGC-27细胞中p-PI3K、p-Akt、B细胞淋巴瘤-2(B-cell lymphoma-2,Bcl-2)、CCNE1和细胞周期蛋白依赖性激酶2(cyclin-dependent kinase 2,CDK2)的蛋白表达(P<0.01),上调GSK-3β、Bcl-2相关X蛋白(Bcl-2 associated X protein,Bax)和剪切型半胱氨酸天冬氨酸蛋白酶-3(cleaved cysteine-aspartate protease-3,cleaved Caspase-3)表达(P<0.05、0.01)。功能回复实验证实,沉默GSK-3β或过表达CCNE1均可部分逆转蟾酥注射液诱导的细胞周期阻滞、凋亡及增殖抑制(P<0.05、0.01)。体内实验结果显示,蟾酥注射液能显著抑制裸鼠移植瘤的生长,促进肿瘤细胞凋亡并抑制肿瘤细胞增殖,下调肿瘤组织中p-PI3K、p-Akt及CCNE1表达,上调GSK-3β表达。结论 蟾酥注射液通过抑制PI3K/Akt信号通路,上调GSK-3β表达,进而下调CCNE1的表达,诱导细胞周期阻滞和凋亡,从而抑制胃癌生长。
[Key word]
[Abstract]
Objective To explore the inhibitory effect and potential mechanism of Bufonis Venenum Injection (蟾酥注射液) on gastric cancer cell proliferation. Methods CCK-8 assay, colony formation assay, flow cytometry and Hoechst 33342 staining were used to investigate the effects of Bufonis Venenum Injection on the proliferation, cell cycle and apoptosis of HGC-27 cells. Targets for treating gastric cancer with Bufonis Venenum Injection were screened through network pharmacology, and differentially expressed proteins in HGC-27 cells treated with Bufonis Venenum Injection were analyzed using proteomics techniques. The intersection was taken to determine the key targets. Core signaling pathways were predicted through gene enrichment analysis and validated using Western blotting. Through in vitro silencing of glycogen synthase kinase-3β (GSK-3β) and overexpression of cyclin E1 (CCNE1), as well as in vivo experiments based on a nude mouse transplant tumor model, the function of core molecular axis was further validated. Results Bufonis Venenum Injection could significantly inhibit the proliferation of HGC-27 cells, with a half inhibitory concentration (IC50) value of 26.56 ng/mL. Bufonis Venenum Injection could induce cell cycle arrest in G0/G1 phase and promote cell apoptosis (P < 0.01). Network pharmacology and proteomics jointly screened 29 key targets, and enrichment analysis revealed that phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) signaling pathway was the core pathway. Western blotting results showed that Bufonis Venenum Injection could downregulate the protein expressions of p-PI3K, p-Akt, B-cell lymphoma-2 (Bcl-2), CCNE1 and cyclin dependent kinase 2 (CDK2) in HGC-27 cells (P < 0.01), and upregulate the expressions of GSK-3β, Bcl-2 associated X protein (Bax) and cleaved cysteine-aspartate protease-3 (cleaved Caspase-3) (P < 0.05, 0.01). Functional recovery experiments confirmed that silencing GSK-3β or overexpression of CCNE1 could partially reverse the cell cycle arrest, apoptosis and proliferation inhibition induced by Bufonis Venenum Injection (P < 0.05, 0.01). The in vivo experimental results showed that Bufonis Venenum Injection could significantly inhibit the growth of transplanted tumors in nude mice, promote tumor cell apoptosis and inhibit tumor cell proliferation, downregulate the expressions of p-PI3K, p-Akt and CCNE1 in tumor tissues, and upregulate the expression of GSK-3β. Conclusion Bufonis Venenum Injection inhibits PI3K/Akt signaling pathway, upregulates the expression of GSK-3β, thereby downregulating the expression of CCNE1, inducing cell cycle arrest and apoptosis, thereby inhibiting the growth of gastric cancer.
[中图分类号]
R285.5
[基金项目]
烟台市科技局项目(2024JCYJ048)